Strategic report Governance & remuneration Financial statements Investor information Notes to the company balance sheet UK GAAP including FRS 101 Reduced Disclosure Framework continued H Trade and other payables 2015 2014 m m Amounts due within one year: Other creditors 478 497 Contingent consideration payable 7 Amounts owed to Group undertakings 186 1,302 671 1,799 The company has guaranteed debt issued by its subsidiary companies from one of which it receives an annual fee.
In aggregate, the company has outstanding guarantees over 16.1 billion of debt instruments.
The amounts due from the subsidiary company in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within Trade and other receivables see Note G. I Provisions 2015 2014 m m At 1 January 25 Charge for the year 139 148 Utilised 127 138 Other movements 3 15 At 31 December 40 25 The provisions relate to a number of legal and other disputes in which the company is currently involved.
J Other non-current liabilities 2015 2014 m m Contingent consideration payable 398 398 The contingent consideration relates to the amount payable for the acquisition in 2015 of the Novartis Vaccines portfolio.
The current year liability is included within Trade and other payables.
K Called up share capital and share premium account Share premium Ordinary Shares of 25p each account Number m m Share capital authorised At 31 December 2014 10,000,000,000 2,500 At 31 December 2015 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2014 5,342,206,696 1,336 2,595 Issued under employee share schemes 13,090,536 3 164 At 31 December 2014 5,355,297,232 1,339 2,759 Issued under employee share schemes 6,010,415 1 72 At 31 December 2015 5,361,307,647 1,340 2,831 31 December 31 December 2015 2014 000 000 Number of shares issuable under outstanding options 99,833 88,801 Number of unissued shares not under option 4,538,859 4,555,902 At 31 December 2015, of the issued share capital, 29,801,412 shares were held in the ESOP Trusts, 491,515,950 shares were held as Treasury shares and 4,839,990,285 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 42, Employee share schemes.
L Reserves The profit of GlaxoSmithKline plc for the year was 656 million 2014 10,003 million, which after dividends of 3,874 million 2014 3,843 million, gave a retained loss of 3,218 million 2014 6,160 million profit.
No Treasury shares were purchased in the year 2014 238 million and no Treasury shares were transferred to a subsidiary 2014 150 million.
At 31 December 2015, the retained earnings stood at 20,033 million 2014 23,251 million, of which 4,096 million was unrealised 2014 4,096 million.
M Group companies See pages 250 to 258 for a complete list of subsidiaries, associates and joint ventures, which form part of these financial statements.
